Loading clinical trials...

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | Clinical Trials | Clareo Health

TERMINATEDPHASE1

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers

NCT03783403•Celgene

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.

Detailed Description

This is a test.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or CD20-positive non-Hodgkin's lymphoma, or diffuse large B cell lymphoma, or follicular lymphoma
•Solid tumors must have at least one site of measurable disease as determined by RECIST v1.1
•Eastern cooperative oncology group performance status of 0 or 1

Exclusion Criteria

•High-grade lymphomas (Burkitt's or lymphoblastic)
•Has cancer with symptomatic central nervous system (CNS) involvement
•History of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months

Locations (31)

Local Institution - 105

Birmingham, Alabama, United States

Local Institution - 101

Scottsdale, Arizona, United States

Local Institution - 112

Sacramento, California, United States

Rocky Mountain Cancer Centers, LLP [Aurora-COAU]

Aurora, Colorado, United States

Local Institution - 115

St Louis, Missouri, United States

Local Institution - 110

New York, New York, United States

Local Institution - 109

Charlotte, North Carolina, United States

Local Institution - 106

Oklahoma City, Oklahoma, United States

Local Institution - 113

Portland, Oregon, United States

Local Institution - 107

Pittsburgh, Pennsylvania, United States

Key Dates

Start Date

March 1, 2019

Primary Completion Date

August 5, 2024

Completion Date

August 5, 2024

Last Updated

September 19, 2024

Enrollment

206

ACTUAL participants

Conditions

Neoplasms

Interventions

CC-95251

DRUG

Rituximab

DRUG

Cetuximab

DRUG

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

NCT07159659

Thoracic Neoplasms

View study

RECRUITING

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Inclusion Criteria

Exclusion Criteria

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer